Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1970 1
1974 1
1980 1
1981 1
1983 2
1984 1
1985 3
1987 4
1988 1
1991 2
1992 1
1993 1
1996 2
1997 2
1999 5
2001 6
2002 7
2003 5
2004 12
2005 8
2006 11
2007 14
2008 23
2009 18
2010 16
2011 16
2012 4
2013 8
2014 11
2015 7
2016 10
2017 12
2018 12
2019 12
2020 11
2021 12
2022 21
2023 25
2024 30
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Results by year

Filters applied: . Clear all
Page 1
CD19: a promising target for systemic sclerosis.
Komura K. Komura K. Front Immunol. 2024 Oct 3;15:1454913. doi: 10.3389/fimmu.2024.1454913. eCollection 2024. Front Immunol. 2024. PMID: 39421745 Free PMC article. Review.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. Mol Cancer. 2023. PMID: 37980528 Free PMC article.
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma.
Nishimura K, Takahara K, Komura K, Ishida M, Hirosuna K, Maenosono R, Ajiro M, Sakamoto M, Iwatsuki K, Nakajima Y, Tsujino T, Taniguchi K, Tanaka T, Inamoto T, Hirose Y, Ono F, Kondo Y, Yoshimi A, Azuma H. Nishimura K, et al. Among authors: komura k. NPJ Precis Oncol. 2024 Sep 17;8(1):206. doi: 10.1038/s41698-024-00707-6. NPJ Precis Oncol. 2024. PMID: 39289546 Free PMC article.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Cancer Sci. 2023 Dec;114(12):4622-4631. doi: 10.1111/cas.15976. Epub 2023 Sep 26. Cancer Sci. 2023. PMID: 37752769 Free PMC article.
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
Yanagisawa T, Mori K, Kawada T, Katayama S, Uchimoto T, Tsujino T, Nishimura K, Adachi T, Toyoda S, Nukaya T, Fukuokaya W, Urabe F, Murakami M, Yamanoi T, Bekku K, Komura K, Takahara K, Hashimoto T, Fujita K, Azuma H, Ohno Y, Shiroki R, Uemura H, Araki M, Kimura T; JK-FOOT study group. Yanagisawa T, et al. Among authors: komura k. Urol Oncol. 2024 Nov;42(11):374.e21-374.e29. doi: 10.1016/j.urolonc.2024.06.013. Epub 2024 Jul 31. Urol Oncol. 2024. PMID: 39085019
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: komura k. Target Oncol. 2024 Jul;19(4):635-644. doi: 10.1007/s11523-024-01068-7. Epub 2024 May 28. Target Oncol. 2024. PMID: 38807017
Current treatment strategies for advanced prostate cancer.
Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Komura K, et al. Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20. Int J Urol. 2018. PMID: 29266472 Free PMC article. Review.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: komura k. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review.
Tanaka T, Nishie R, Ueda S, Miyamoto S, Hashida S, Konishi H, Terada S, Kogata Y, Sasaki H, Tsunetoh S, Taniguchi K, Komura K, Ohmichi M. Tanaka T, et al. Among authors: komura k. J Clin Med. 2022 May 6;11(9):2606. doi: 10.3390/jcm11092606. J Clin Med. 2022. PMID: 35566732 Free PMC article. Review.
Perspective to precision medicine in scleroderma.
Komura K, Yanaba K, Bouaziz JD, Yoshizaki A, Hasegawa M, Varga J, Takehara K, Matsushita T. Komura K, et al. Front Immunol. 2024 Jan 18;14:1298665. doi: 10.3389/fimmu.2023.1298665. eCollection 2023. Front Immunol. 2024. PMID: 38304250 Free PMC article.
302 results